DEF: Shuttle Pharmaceuticals Launches Phase 2 Trial, Seeks Reverse Stock Split Approval

Shuttle Pharmaceuticals reports progress on its lead program, Ropidoxuridine, and seeks shareholder approval for a reverse stock split to maintain Nasdaq compliance.

Summary

• Shuttle Pharmaceuticals is advancing its lead program, Ropidoxuridine, with a Phase 2 trial for glioblastoma treatment.
• Enrollment in the trial has met expectations, with 43% of the initial 40 patients enrolled as of the letter's writing.
• The company aims to finalize enrollment later this year, with data readout expected in 2026.
• Shuttle Pharmaceuticals is also developing other assets, including an HDAC6 selective inhibitor (SP-2-225) and diagnostics for prostate cancer.
• The company completed a $5.75 million common stock offering in March 2025 to support the Phase 2 trial and other corporate purposes.
• The company is seeking shareholder approval for a reverse stock split in the range of 1-for-3 to 1-for-10 to regain compliance with Nasdaq's minimum bid price requirement.
• The company is also seeking shareholder approval to increase the number of shares reserved for issuance under the 2018 Equity Incentive Plan by 5,000,000 shares.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. There's positive progress in clinical trials and business development, but concerns about Nasdaq compliance and the need for a reverse stock split temper the outlook.

Positives

• Successful launch of the Phase 2 trial of Ropidoxuridine for glioblastoma treatment.
• Robust enrollment in the clinical trial, meeting all expectations.
• Advancement of a robust development portfolio, including therapeutics and diagnostics.
• Appointment of Christopher Cooper as interim CEO to enhance capital markets and business capabilities.
• Addition of three new members to the board of directors with business and legal backgrounds.
• Completion of a $5.75 million straight common stock offering.

Negatives

• The company received a notice from Nasdaq for failing to maintain a minimum bid price of $1.00 per share.
• The company needs to effectuate a reverse stock split in order to regain compliance with the Minimum Bid Price Requirement prior to June 30, 2025 and maintain its listing on the Nasdaq Capital Markets.

Risks

• Failure to maintain compliance with Nasdaq's minimum bid price requirement could lead to delisting.
• Delisting from Nasdaq could negatively impact the liquidity and trading volume of the common stock.
• The reverse stock split may not result in a sustained increase in the per share price of the common stock.
• The company is dependent on expanding access to the capital markets.

Future Outlook

The company aims to finalize enrollment in the Phase 2 trial later this year, with data readout expected in 2026. They also plan to submit applications for NIH funding and seek collaborations or joint ventures to support further development of selected preclinical assets.

Management Comments

• It is with great excitement that I write to review the key milestones that have been reached over the past year and those that remain in focus to advance Shuttle Pharmas mission to improve outcomes for cancer patients receiving radiation therapy (RT).
• I look forward to continued trial execution as we aim to improve the lives of millions of patients impacted by cancer and to bring hope to patients and families around the world.
• At Shuttle Pharma, our mission is to launch the next generation of drugs to improve outcomes and achieve more cures for cancer patients undergoing radiation treatments.
• I thank our team and investors for continued support as Shuttle Pharmas drugs achieve scientific milestones on a path to commercialization and clinical application.

Industry Context

The document highlights the company's efforts to leverage radiation sensitizers to increase cancer cure rates, prolong patient survival, and improve the quality of life for patients suffering from glioblastoma, which aligns with broader industry trends in radiation therapy and oncology.

Comparison to Industry Standards

• The document mentions collaborations with nationally recognized East Coast cancer centers, including UVA Cancer Center, Miami Cancer Institute, and John Theurer Cancer Center, indicating a commitment to high standards of cancer care.
• The company's focus on developing radiation sensitizers and theranostic molecules aligns with industry trends in personalized medicine and targeted cancer therapies.
• The company's engagement with Georgetown University and the University of California, San Francisco (UCSF) for research and development suggests a commitment to scientific rigor and innovation.

Management Changes

Corporate Governance

Related Party Transactions

• The company entered into a loan agreement with Dr. Anatoly Dritschilo, pursuant to which Dr. Dritschilo loaned the Company of $250,000 (principal), bearing interest at the rate of 12% per annum and which is repayable in 12 substantially equal monthly installments over a one-year period.
• The company entered into a securities purchase agreement with Dr. Anatoly Dritschilo, issuing a $250,000 5% original issue discount senior secured convertible note and warrants to purchase up to a total of 100,382 shares of common stock at an exercise price per share equal to $1.40 per share.
• The company entered into a loan agreement with Dr. Anatoly Dritschilo, pursuant to which Dr. Dritschilo loaned the Company of $75,000 (principal), bearing interest at the rate of 14% per annum and which is repayable with accrued interest in one month.

Stakeholder Impact

• Shareholders are asked to vote on key proposals, including the election of directors, ratification of the independent auditor, approval of executive compensation, authorization of a reverse stock split, and approval of an amendment to the equity incentive plan.
• Employees may be impacted by changes in executive leadership and potential changes to the equity incentive plan.
• Patients may benefit from the company's efforts to develop new cancer treatments.
• The company's financial performance and Nasdaq compliance could impact investor confidence and the company's ability to raise capital.

Next Steps

• Finalize enrollment in the Phase 2 clinical trial of Ropidoxuridine.
• Conduct follow-up and data readout in 2026.
• Submit applications for NIH funding and seek collaborations or joint ventures.
• Initiate a clinical trial for clinical validation of the PC-Rad Test.
• Further preclinical testing of the PSMA-B ligand in a mouse model of prostate cancer.
• Seek shareholder approval for the reverse stock split and the amendment to the 2018 Equity Incentive Plan.
• The Board of Directors will determine whether and when to effect the Reverse Stock Split.

Key Dates

Keywords

Ropidoxuridine, glioblastoma, clinical trial, reverse stock split, radiation therapy, cancer, diagnostics, therapeutics, Nasdaq, shareholders